Rosalind Franklin University of Medicine and Science announced today that BLR Bio, a company in its Helix 51 incubator, ...

VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...

Sanofi shares fell after an experimental treatment for multiple sclerosis was hit by a double setback, with results of a late-stage study missing a key goal and U.S. regulators signaling a decision on ...

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus (ocrelizumab). The company announced that a phase III study, MUSETTE, which ...

Roche Holding said a drug candidate for multiple sclerosis met the primary goal in a late-stage clinical trial in the most common form of the disease. The Swiss pharmaceutical company said Monday that ...

By Marleen Kaesebier and Patricia Weiss ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that ...

On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive ...

Stifel on Thursday initiated coverage on Immunic Inc. IMUX, a late-stage biotechnology company developing oral therapies for ...